The Influence of Capox (Xelox) and Folfox on Colorectal Cancer Patients in Tripoli University Hospital, Tripoli, Libya

Abstract

Background/Aims: Colorectal cancer (CRC) is the fourth most common cancer in the world with 1.3 million new cases each year and a 5-year prevalence rate of 3.2 million. The purpose of this study was to evaluate and to provide information about the toxicity and side effects of the two chemotherapies (Capox and Folfox), which used for CRC treatment in Oncology Department in Tripoli University Hospital (TUH), Tripoli, Libya. Methods: The study conducted over a period of four-years (2016-2020) and a total of 100 CRC patients who receive chemotherapy (Capox or Folfox). The study follows the effect of the two chemotherapies, as well as CRC progression and recurrence. CT and PET-CT scan were used for screening patients for early-stage CRC and used from time to time to make sure that the cancer has not recurrence after treatments. Results: Out of 35 patients used Capox chemotherapy and 35 patients used Folfox chemotherapy 22 and 24 patients had remission. Conclusion: Both chemotherapies (Capox and Folfox) had an equal impact on CRC patients. As a result, Capox is a more convenient option for patient’s comfort, as well as a better option in terms of cost and also saves time and money.